Tests ruxolitinib with tacrolimus and methotrexate to prevent graft versus host disease after transplant
Tests ruxolitinib with other drugs in young people having stem cell transplants for leukemia.
Key facts
- Who runs it
- City of Hope Medical Center
- Where
- Duarte, United StatesSee the site
- Trial code
- Registry title
- Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 1 Aug 2024
- Expected to end
- 22 Nov 2030
- Type of study
- Interventional
- Treatments tested
- Biospecimen Collection
- Chest Computed Tomography
- Echocardiography
- Hematopoietic Cell Transplantation
- Methotrexate
- Multigated Acquisition Scan
- Ruxolitinib Phosphate
- Tacrolimus
- Record updated
- 14 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults aged 2 to 22 who will have a donor stem cell transplant for acute leukemia in remission or myelodysplastic syndrome. It tests ruxolitinib added to tacrolimus and methotrexate to prevent graft versus host disease.
- Age
- 2 to 22 years
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia or acute lymphoblastic leukemia in complete remission, or myelodysplastic syndrome.
- Earlier treatment
- Must have recovered from side effects of earlier cancer treatment to grade 1 or milder. Must not have had a prior allogeneic transplant, or an autologous stem cell transplant within 1 year. No chemotherapy, radiation, biological therapy or immunotherapy within 14 days before starting.
Main reasons for not taking part
- Prior allogeneic transplant
- Known HIV, hepatitis B or hepatitis C infection
- Active uncontrolled infection needing antibiotics
- History of blood clots (such as stroke, heart attack, pulmonary embolism, DVT) within 6 months
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Documented informed consent of the participant and/or legally authorized representative; Assent, when appropriate, will be obtained per institutional guidelines
- Agreement to allow the use of archival tissue from diagnostic tumor biopsies; If unavailable, exceptions may be granted with study primary investigator (PI) approval
- Age: 2-22
- Weight ≥25kg
- Eastern Cooperative Oncology Group (ECOG) ≤ 2
- Performance status: Karnofsky ≥ 60% for patients ≥ 16 years old OR Lansky status ≥ 60% for patients < 16 years old
- Candidate for allogeneic bone marrow transplant with and available matched related donor (MRD) or an 8/8 matched unrelated donor (MUD) who is willing to donate bone marrow (BM) or mobilized peripheral blood stem cells; Note: Donor selection process will be in accordance with City of Hope (COH)-standard operating procedures (SOPs) (B.001.09 Allogeneic Cellular Therapy Product Donor Evaluation, Selection \& Consent), which follows Food and Drug Administration (FDA) guidelines for donation of hematopoietic stem/progenitor cells (HPCs) obtained from peripheral blood or bone marrow
- Diagnosis of acute leukemia (acute myeloid leukemia [AML] or acute lymphoblastic leukemia [ALL]) in complete remission, or myelodysplastic syndrome (MDS)
- Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 from prior anti-cancer therapy
- Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (to be performed within 30 days prior to day 1 of protocol therapy)
- Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy; Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
Who cannot take part
- Autologous stem cell transplant within 1 year prior to day 1 of protocol therapy
- Prior allogeneic transplantation
- Chemotherapy, radiation therapy, biological therapy, immunotherapy within 14 days prior to day 1 of protocol therapy; Note: Conditioning regimen within 21 days prior to day 1 of protocol therapy is not considered as an exclusion criterion; Note: Patients on maintenance chemotherapy with agents listed are not excluded
- Herbal medications
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
- History of active tuberculosis
- Patients with history of thrombosis including but not limited to myocardial infarction (MI)/stroke and pulmonary embolism (PE)/deep vein thrombosis (DVT) within 6 months of enrollment
- Active diarrhea due to inflammatory bowel disease or malabsorption syndrome
- Clinically significant uncontrolled illness
- Active, uncontrolled systemic infection (viral, bacterial, or fungal) requiring antibiotics
- Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection
- Other active malignancy
- Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
- Females only: Pregnant or breastfeeding
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 22 years old?
Where in United States
- City of Hope Medical CenterDuarte, United StatesContact: Haris AliTaking people
About the trial
What the trial wants to find out
This phase II trial tests how well ruxolitinib with tacrolimus and methotrexate work to prevent the development of graft versus host disease in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. Ruxolitinib is a type of medication called a kinase inhibitor. It works by blocking the signals of cells that cause inflammation and cell proliferation, which may help prevent graft versus host disease (GVHD). Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants by suppressing the immune system. Methotrexate stops cells from making DNA, may kill cancer cells, and also suppress the immune system, which may reduce the risk of GVHD. Giving ruxolitinib with tacrolimus and methotrexate may prevent GVHD in pediatric and young adults undergoing allogeneic hematopoietic cell transplants.
The group in the trial
- Prevention (Ruxolitinib, tacrolimus, methotrexate)Treatment being tested
Patients receive ruxolitinib PO BID from day -1 to day +100, tacrolimus IV on day -1, and methotrexate IV on days +1, +3, +6, and +11, and undergo HCT on day 0. Patients also undergo chest CT and ECHO/MUGA at screening and undergo collection of blood samples throughout the trial.
Treatment: Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate, Multigated Acquisition Scan, Ruxolitinib Phosphate, and Tacrolimus
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase 2a Study of Adding Ruxolitinib With Tacrolimus/Methotrexate Regimen for Graft-versus-Host Disease Prophylaxis in Myeloablative Conditioning Hematopoietic Cell Transplantation in Pediatric and Young Adult Patients
- Plain-language title
- Tests ruxolitinib with tacrolimus and methotrexate to prevent graft versus host disease after transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06128070, who can take part
- Record updated
- 14 October 2026